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Abstract
Background:  Deregulated activation of cyclin-dependent kinase-5 (Cdk5) is implicated in
neurodegenerative disorders such as Alzheimer's disease. One of the restricting factors for
developing specific Cdk5 inhibitors is the lack of reproducible and well-characterized cellular in
vitro assay systems.
Methods: HEK293 cells were transfected with Cdk5 and its activator p25 as a starting point for
an assay to screen for Cdk5 kinase inhibitors. To identify suitable substrates for Cdk5 we utilized
an antibody that recognizes phospho serine in a consensus motif for Cdk substrates.
Results: Western blot analysis of transfected cells detected a 200 kDa band that was identified, by
mass spectrometry, as non-muscle myosin heavy chain, type B (NMHC-B). Phosphorylation of
NMHC-B was evident only in cells that were double transfected with Cdk5/p25 and was dose-
dependently inhibited by Roscovitine and other Cdk5 inhibitors. Cdk5 was found to phosphorylate
NMHC-B also in the human neuroblastoma SH-SY5Y cell line.
Conclusion: A novel Cdk5 substrate NMHC-B was identified in this study. A cellular assay for
screening of Cdk5 inhibitors was established using NMHC-B phosphorylation as a read-out in
Cdk5/p25 transfected HEK293 cells. A novel Cdk5 inhibitor was also pharmacologically
characterized in this assay system.
Background
Cyclin-dependent kinase-5 (Cdk5) is a member of the cyc-
lin-dependent kinase (Cdk) family of serine/threonine
kinases [1]. Unlike other Cdk's, Cdk5 is not regulated by
cyclins and is not involved in cell cycle control. The activ-
ity of Cdk5 is regulated by its binding to neuron-specific
activator proteins, p35 and p39, [2,3] and by phosphor-
ylation [4]. Although Cdk5 is widely expressed, its kinase
activity is detected primarily in the nervous system,
mainly because highest expression of its activators is
restricted to post-mitotic neurons [5].
Although Cdk5 activity is necessary for many physiologi-
cal functions and development of the nervous system,
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deregulated Cdk5 activity is neurotoxic and has been
linked to neurodegenerative diseases such as Alzheimer's
disease (AD). Conversion of p35 to p25 by the calcium
activated protease calpain, is thought to cause deregula-
tion of Cdk5 activity in AD brain [6,7]. The dimeric Cdk5/
p25 has been shown to possess prolonged enzymatic
activity and potentially alter its cellular localization and
substrate specificity of the kinase [6,7]. In AD brain, Cdk5
is thought to hyperphosphorylate tau protein and thus
contribute to the formation of neurofibrillary tangles, one
of the two major pathological hallmarks of this disease [6-
8]. Deregulation of Cdk5 also occurs in other neurodegen-
erative disorders such as Parkinson's disease [9] and
amyotrophic lateral sclerosis [10]. Cdk5 is also implicated
in ischemic cell death [11] and contextual fear [12].
Although Cdk5 is crucial for learning and memory, pro-
longed activity is detrimental and impairs these processes
[13-15].
Taken together, data supporting the role of Cdk5 in differ-
ent pathways connected to pathological processes in the
central nervous system is convincing thus making it a
potentially important target for drug research. Further-
more, availability of specific and selective Cdk5 inhibitors
would enable even more detailed studies on its patholog-
ical and biological roles. One of the restricting factors for
identifying specific Cdk5 inhibitors is the lack of a repro-
ducible and well-characterized cellular assay system. One
of the major reasons is the almost exclusive localization of
the active Cdk5/p35(p25) complex to cells of neuronal
origin, which makes it difficult to find easy-to-handle cell
lines for assay purposes.
We previously investigated retinoic acid and brain-derived
neurotrophic factor (RA-BDNF) differentiated SH-SY5Y
cells in an attempt to establish a cellular system to study
Cdk5 involvement in tau phosphorylation. However, in
basal conditions the involvement of Cdk5 in tau phos-
phorylation is minor [16] and also in stimulated cells
increases in tau phosphorylation are very moderate or
obscured by the involvement of other kinases [17]. There-
fore, we proceeded to investigate HEK293 cells transfected
with Cdk5/p25 to identify alternative substrates with a
robust phosphorylation signal that would enable charac-
terization of enzyme inhibitors.
We report the establishment of a new cellular screening
system, which enables pharmacological characterization
of specific Cdk5 inhibitors. In the course of the study, we
also identified non-muscle myosin heavy chain, type B
(NMHC-B), as a substrate for Cdk5.
Materials and methods
Cell cultures, transfections and treatments
HEK293 cells
Human embryonic kidney 293 (HEK293) cells were
grown in Dulbecco's Modified Eagle Medium (D-MEM,
InVitrogen, Sweden) with 4.5 g/l glucose, 2 mM
glutamine and 110 mg/l sodium pyruvate. The medium
was supplemented with 1% non-essential amino acids
(InVitrogen, Sweden) and 10% heat-inactivated Fetal Calf
Serum (FCS, HyClone, Logan, Utah, USA). For transfec-
tion experiments, the cells were plated at a density of 2.0
× 105 cells/cm2 in 6-well culture dishes (Corning, Lowell,
MA, USA). Day 1 after plating, the cells were transfected
with equal amount of p25 plasmid (pAPC227, Molecular
Pharmacology, AstraZeneca R&D, Södertälje, Sweden)
and Cdk5 plasmid (pAPC226, Molecular Pharmacology,
AstraZeneca R&D, Södertälje, Sweden), 1.5 μg each. Lipo-
fectamine™2000 (InVitrogen, Sweden) was used as a
transfection reagent. Lipofectamine™2000 (7.5 μl/trans-
fection) was first diluted in cell culture medium without
FCS and incubated for 5 min at RT. The plasmid DNA
diluted in medium was then combined with Lipo-
fectamine and incubated for further 20 min at RT. The
complexes were added to the cells and the transfection
was carried out for 24 hours. Treatment with Cdk5 inhib-
itors was carried out during the last 4 hours of transfec-
tion.
The p25 and Cdk5 genes were cloned into mammalian
expression vectors, pcDNA3 and pcDNA3.1(-) (Molecular
Pharmacology, AstraZeneca R&D, Södertälje, Sweden),
respectively and the expression was under the control of
CMV promoter. Cdk5 inhibitors used in this study were
Roscovitine (Sigma, Sweden), 7-ethyl-4-[(4-fluorophe-
nyl) amino]-3,5,7-triaza bicyclo [4.4.0.] deca-1,3,5,9-
tetraen-8-one from Warner Lambert company (WL com-
pound)(Medicinal Chemistry, AstraZeneca R&D,
Södertälje, Sweden) [18,19] and 4-(6-chlorobenzothia-
zol-2-yl)thiophene-2-sulfonamide (AZ com-
pound)(Medicinal Chemistry, AstraZeneca R&D,
Södertälje, Sweden) [20]. Stock solutions of Cdk5 inhibi-
tors were prepared in dimethyl-sulfoxide (DMSO). All
cultures including the control cells received equal
amounts of DMSO, the final concentration being 0.158%.
SH-SY5Y cells
SH-SY5Y cells were grown in medium with equal amount
of Minimum Essential Medium (MEM, InVitrogen, Swe-
den) and Nutrient Mixture Ham's F-12 (InVitrogen, Swe-
den), supplemented with 1% non-essential amino acids
and with heat-inactivated FCS. Cells were plated at a den-
sity of 4.0 × 104 cells/cm2 in 6-well culture dishes using
cell medium with 10% FCS. For differentiation, the cells
were treated 6 days with 10 μM all-trans-retinoic acid (RA,
Sigma, Sweden) in the medium containing 1% FCS. InJournal of Biomedical Science 2009, 16:55 http://www.jbiomedsci.com/content/16/1/55
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some experiments the cells were left undifferentiated and
these cells were cultured in medium containing 10% FCS.
SH-SY5Y cells have high endogenous levels of Cdk5 and
therefore only the p25 plasmid (pAPC227) was trans-
fected to the cells. Transfections were carried out in the
same manner as for HEK293 cells except that 10 μl of
Lipofectamine™2000 was used for each transfection with
8 μg p25 plasmid.
Western blot
HEK293 cells were lysed in buffer containing 10 mM Tris-
HCl pH 7.2, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 1
mM Na3O4V, 0.5% NP-40 and 1 complete protease inhib-
itor cocktail tablet (Roche Diagnostics Scandinavia AB,
Sweden)/10 ml buffer. Lysis buffer for SH-SY5Y cells con-
tained 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM
EDTA, 10 mM NaF, 1 mM Na3VO4,1% Triton X-100 and
1 complete protease inhibitor cocktail tablet/10 ml buffer.
Cell lysates were centrifuged at 14 000 rpm (Eppendorf
5417R, Germany) for 15 min. The protein content in the
supernatants was measured using BCA Protein Assay kit
(Pierce Biotechnology, Rockford, IL, USA). Samples con-
taining 40–50 μg protein were resolved in 10%
NuPage®Bis-Tris gels (Invitrogen, Sweden) and the pro-
teins were transfered to Hybond nitrocellulose mem-
branes (Amersham Biosciences, Sweden). Membranes
were blocked in PBS with 0.05% Tween 20 containing 5%
nonfat dry milk for 1 hour at room temperature (RT). Pri-
mary antibodies were diluted in either 5% BSA or 5% milk
and incubations were carried out at 4°C over night. Pri-
mary antibodies were used at the following dilutions:
Cdk5 (C-8; Santa Cruz Biotechnology Inc., Santa Cruz,
California, USA) 1:2000, p35 (C-19; Santa Cruz Biotech-
nology Inc., Santa Cruz, California, USA) 1:2000, pSer
Cdk substrate (Cell Signaling Technology Inc., Danvers,
Massachuesetts, USA) 1:800 and non-muscle heavy chain
myosin [3H2] (abcam, UK) 1:1000. Horseradish-peroxi-
dase (HRP) conjugated secondary antibodies (Amersham
Biosciences, Sweden) were incubated 1 hour at RT in 5%
milk at the dilution of 1:5000 for anti-rabbit and 1:10 000
for anti-mouse antibody. Blots were developed using the
enhanced chemiluminescence (ECL) Western blotting
detection system (Amersham Biosciences, Sweden).
When needed, membranes were stripped with Restore
Western blot stripping buffer (Pierce Biotechnology,
Rockford, IL, USA) for 30 min at 50°C. Average density of
the bands was measured in Fluor-S™MultiImager (Bio-
Rad Laboratories AB, Sweden) by using Quantity One
software. The inhibition curves were analysed by non-lin-
ear regression using Graph Pad Prism.
Immunoprecipitation
200 μg of protein in 100 μl lysis buffer was precleared for
1 hour at 4°C with 10 μl protein A/G Plus agarose beads
(Santa Cruz Biotechnology Inc., Santa Cruz, California,
USA). The samples were centrifuged at 14 000 rpm
(Eppendorf 5417R) for 1 min and the supernatants were
transferred to new tubes. 10 μl of pSer Cdk substrate anti-
body was added to the supernatants and incubated rotat-
ing over night at 4°C, 20 μl protein A/G Plus agarose
beads was added and incubated further for 1 hour. The
samples were centrifuged at 6000 rpm (Eppendorf
5417R) for 2 min. The supernatants were discarded and
the pellets washed three times in 150 μl lysis buffer. The
immunoprecipitates were then diluted in lysis buffer and
processed for Western blot analysis.
Mass spectrometry and sequence analysis
Protein spots of interest were excised from gels using a
spot cutter robot (Bio-Rad, Hercules, CA, USA) and trans-
ferred to 96-well plates. The gel plugs were transferred to
eppendorf tubes approximately 10 pieces in each tube.
Sypro Ruby® (Molecular Probes, the Netherlands)-stained
gel pieces were manually treaded as follows; wash with
100 μl ddH2O three times for 15 min, followed by wash
with 25 mM ammoniumbicarbonate/acetonitril (1:1 v/v)
three times for 15 min. Thereafter acetonitril was added to
cover the gel pieces to shrink them down. The gel pieces
were rehydrated by incubating with 50 μl 25 mM ammo-
niumbicarbonate for 5 min, adding acetonitril and incu-
bating for another 15 min. Thereafter all liquid was
removed and the gel pieces were dried completely in
vacuo. The samples were placed on ice and a freshly pre-
pared and chilled digestion solution containing 10 ng/μl
of trypsin (Promega, Madison, WI, USA) in 25 mM
ammoniumbicarbonate was added to cover the gel pieces.
Incubation on ice for 10 min and in RT for 30 min was
carried out and more buffer was added if necessary. The
samples were then placed on a heater at 37°C over night.
One-hour incubation with equal amount of 1% formic
acid stopped the reaction. To concentrate and desalt the
samples ZipTip (Millipore, Billerica, Massachuesetts,
USA) was used according to manufacturers descriptions.
Samples were then washed twice with 1% formic acid and
eluted with 2 μl of matrix solution α-cyano-4-hydroxycin-
mic acid (Waters Corporation, Milford, Massachusetts,
USA) direct onto 96-position MALDI target plate (Waters
Corporation, Milford, Massachusetts, USA) and crystals of
matrix and peptide were formed. After MALDI-ToF
(Waters Corporation, Milford, Massachusetts, USA) was
used to attain the mass of each peptide and the resulting
peaklist was imported into the search engineers Protein
Lynx Global Server 2 (PLGS2, Waters Corporation, Mil-
ford, Massachusetts, USA) and MASCOT (Matrix Sciences
Ltd, UK). Several databases were selected as information
sources.
Scintillation Proximity Assay
The assay experiments were carried out in duplicate with
10 different concentrations of the inhibitors in clear-bot-Journal of Biomedical Science 2009, 16:55 http://www.jbiomedsci.com/content/16/1/55
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tom 384-well microtiter plates (Item No 3706, Corning,
Lowell, Massachusetts, USA). Recombinant human Cdk5/
p25 (Biotech Laboratory, AstraZeneca R&D, Södertälje,
Sweden) was added at a final concentration of 3.3 nM in
an assay buffer containing 23.3 mM HEPES, pH 7.35, 0.2
mM EDTA, 12.5 mM KCl, 10 mM β-glycerophosphate,
0.02% β-mercaptoethanol, 0.007% Brij 35, 0.8% glycerol
and 0.05% BSA. After incubation for 15 min the reaction
was initiated by the addition of 2.95 μM (final concentra-
tion) of a biotinylated peptide substrate, Biotin-Ala-Lys-
Lys-Pro-Lys-Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu-OH
(Bachem, Switzerland), 0.07 μCi [γ33P]ATP (Amersham,
UK), 2 μM unlabelled ATP and 10 mM MgCl2 in an final
assay volume of 21 μl. After incubation for 40 min at RT,
each reaction was terminated by the addition of 30 μl stop
solution containing 24 mM EDTA, 2.2 mM ATP and 0.225
mg streptavidine coated SPA beads (Amersham, UK). The
microtiter plates were centrifuged for 2 minutes at 200 g
and the radioactivity was determined in a liquid scintilla-
tion counter (1450 MicroBeta Trilux, Wallac, Finland).
The inhibition curves were analysed by non-linear regres-
sion using Graph Pad Prism.
Results
Transfection of HEK293 cells with Cdk5/p25 reveals one 
phosphoprotein that can be inhibited with Roscovitine
To identify novel Cdk5 substrates suitable for characteris-
ing enzyme inhibitors, we transfected HEK293 cells with
Cdk5 and p25 to get an active Cdk5/p25 complex. Cell
lysates from transfected cells were analyzed with Western
blotting using an antibody that recognizes phospho serine
in a consensus motif for Cdk substrates.
The pSerCdk substrate antibody recognized several phos-
phoproteins. A band with molecular weight of approxi-
mately 200 kDa appeared in cells that were double
transfected with Cdk5 and p25 but did not show up in
non-transfected or single transfected (only Cdk5 or p25)
cells (Fig. 1A). The 200 kDa band decreased in intensity in
Cdk5/p25 transfected cells treated with 1 μM Roscovitine
(Fig. 1A). The other bands were visible even with single
transfection and were not inhibited by Roscovitine. We
therefore concluded that only the 200 kDa band is regu-
lated by Cdk5.
In initial studies, the HEK293 cells were transfected with
1, 1.5 or 2 μg of Cdk5 and p25 plasmids. The setting
where the cells were transfected with 1.5 μg of each plas-
mid, i.e. 3 μg total plasmid DNA, showed least effect on
cell morphology and viability (data not shown) with suf-
ficient phosphorylation of Cdk substrates (Fig 1B). This
plasmid concentration was therefore chosen for all further
experiments.
Cdk5 phosphorylates non-muscle myosin heavy chain in 
Cdk5/p25 transfected HEK293 cells
Mass spectrometry identified the 200 kDa band as a non-
muscle myosin heavy chain, type B (NMHC-B) (GenBank
access number P35580). The total number of mass values
matched was 130 and the sequence coverage 57%. Verifi-
cation that the 200 kDa pSerCdk substrate band indeed
was myosin was done by immunoprecipitation. When
Cdk5/p25 transfected samples were immunoprecipitated
with pSerCdk substrate antibody and then run on Western
blot, the pSerCdk substrate antibody and NMHC-B anti-
body detected the same band (Fig 1C). Western blot anal-
ysis of cell lysates gave the same results (data not shown).
Cdk5 inhibitors dose-dependently inhibit peptide substrate 
phosphorylation in a Scintillation proximity assay
Initial identification of potent Cdk5 inhibitors was done
in a Scintillation Proximity Assay (SPA). This biochemical
assay measures inhibition of the recombinant human
Cdk5/p25 protein kinase by different compounds with a
synthetic peptide as a substrate. Several compounds dis-
played a potency in the nanomolar range and were further
tested in Cdk5/p25 transfected HEK293 cells. Figure 2
shows structures and SPA results from three representative
compounds, Roscovitine, a WL compound and 4-(6-chlo-
robenzothiazol-2-yl)thiophene-2-sulfonamide (an AZ
compound). IC50 values in SPA assay were 280 nM for
Roscovitine (Fig 2A), 45 nM for the WL compound (Fig
2B) and 355 nM for the AZ compound (Fig 2C).
Cdk5 inhibitors dose-dependently inhibit non-muscle 
myosin heavy chain phosphorylation in HEK293 cells
To further investigate Cdk5 involvement in NMHC phos-
phorylation, we used the three pharmacological inhibi-
tors of Cdk5 and analyzed NMHC phosphorylation by
Western blot using the pSerCdk substrate antibody.
The Cdk5 inhibitors Roscovitine, WL and AZ compounds
concentration-dependently inhibited pSerCdk substrate
phosphorylation with IC50 of 1.18 μM, 2.55 μM and 4.36
μM, respectively. (Fig 3A, B, C). As a comparison, a non-
kinase inhibitor 5-(4-chlorobenzoyl)-2-hydroxy-6-
methyl-3-tert-butyl-benzoic acid (Medicinal Chemistry,
AstraZeneca R&D, Södertälje, Sweden) did not show inhi-
bition of pSerCdk substrate phosphorylation (data not
shown).
Cdk5 phosphorylates non-muscle myosin heavy chain in 
human neuroblastoma SH-SY5Y cells
We also investigated NMHC-B phosphorylation by Cdk5
in human neuroblastoma SH-SY5Y cells. The 200 kDa
pSerCdk substrate band was detected both in undifferen-
tiated and RA-differentiated SH-SY5Y cells and phosphor-
ylation could be completely inhibited with 10 μM
Roscovitine (Fig. 4A). Verification that the 200 kDa pSer-Journal of Biomedical Science 2009, 16:55 http://www.jbiomedsci.com/content/16/1/55
Page 5 of 11
(page number not for citation purposes)
Figure 1 (see legend on next page)
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Cdk band detected in SH-SY5Y cells was in fact NMHC-B
was done by immunoprecipitation. When samples from
undifferentiated SH-SY5Y cells were immunoprecipitated
with pSerCdk antibody and then run on Western blot,
pSerCdk antibody and NMHC-B antibody detected the
same band (Fig. 4B). pSerCdk substrate phosphorylation
did not increase in intensity in p25 transfected cells, either
in RA-differentiated (Fig. 4C, D) or undifferentiated (data
not shown).
Discussion
As Cdk5 kinase activity is almost exclusively restricted to
neuronal post-mitotic cells, it has been challenging to
identify both a specific and robust cellular assay to enable
pharmacological characterization of enzyme inhibitors.
In an attempt to identify a suitable system, we set up to
transfect HEK293 cells, with both the Cdk5 enzyme and
its activator p25.
Previously, a wide variety of substrate proteins have been
identified for Cdk5, which reflects its role in diverse func-
tions. For instance, Cdk5 is involved in regulation of
cytoskeletal dynamics by phosphorylating neurofilaments
and microtubule-associated proteins tau and MAP1B [21-
23]. Cdk5 participates in synaptic function and neuro-
transmission by phosphorylating many synaptic proteins
[24]. In addition, Cdk5 has an important function in the
development of the central nervous system regulating
neuronal migration [25] and axon guidance [26].
As Cdk5 phosphorylates serines and threonines immedi-
ately upstream of a proline residue [27], an antibody that
recognizes phospho serine in this consensus motif for
Cdk substrate, was utilized in our study. As a result, a non-
muscle myosin heavy chain, type B (NMHC-B) was iden-
tified as a Cdk5 substrate. Myosins constitute a large fam-
ily of actin-based motor proteins [28] and non-muscle
myosins are composed of two heavy chains and two pairs
of light chains. In contrast to muscle myosins, which form
stable myofibrils, the non-muscle myosin constitutes part
of the actinomyosin cytoskeleton. Both actin and myosin
in non-muscle cells can be rapidly assembled or disassem-
bled in response to extracellular signals to allow cell shape
changes needed for movement, cell division or secretion
[29,30]. Functional activities of myosin are regulated by
light chain and heavy chain phosphorylation [29].
In vertebrates, NMHC are phosphorylated by kinases such
as Protein Kinase C, Casein kinase II and Ca2+/calmodu-
lin-dependent protein kinase [31,32]. Phosphorylation of
NMHC by Cdk5 has not been demonstrated previously
although a link between Cdk5 and non-muscle myosin
was recently discovered. Ledee et al. [33] showed a specific
interaction between Cdk5 activator p39 and non-muscle
myosin essential light chain.
To test the physiological relevance of our finding, NMHC-
B phosphorylation by Cdk5 was investigated in a second
cell line, a human neuroblastoma SH-SY5Y. HEK293 cells
only express Cdk5 at low levels and they lack endogenous
Cdk5 activity, whereas SH-SY5Y cells express both Cdk5
and its activator p35 and exhibit basal Cdk5 activity [17].
NMHC-B phosphorylation by Cdk5 was also detected in
SH-SY5Y cells, both in undifferentiated and RA-differenti-
ated ones. However, when p25 was transfected to the
cells, no increase in phosphorylation of NMHC-B was
observed in contrast to transfected HEK293 cells where
phosphorylation was dose-dependent on plasmid con-
centration. This could be due to the fact that NMHC-B is
already maximally phosphorylated by endogenous Cdk5
kinase activity.
In drug discovery research, it is customary that the first fil-
tering assay used in compound characterization is a fast,
readily reproducible, miniaturizable and in most cases
biochemical assay. The primary purpose for this system is
to serve as a means of ranking the compounds according
to potency. Thereafter, the chemically most interesting
and potent compounds need to be further characterized
in more complex cellular environment. For Cdk5/p25 we
describe here a HEK293 cell system with quantification of
NMHC-B phosphorylation as read-out. The compounds
tested in the present setting represent different chemical
classes, with the known Cdk inhibitor, Roscovitine, a
Transfection of Cdk5/p25 into HEK293 cells identifies NMHC-B as a substrate for Cdk5 Figure 1 (see previous page)
Transfection of Cdk5/p25 into HEK293 cells identifies NMHC-B as a substrate for Cdk5. A. Western blot showing 
pSerCdk substrate, Cdk5 and p25 levels in cells transfected with Cdk5/p25, Cdk5/p25 transfected cells treated with 1 μM Ros-
covitine, cells transfected only with p25 or Cdk5 and untransfected cells. A 200 kDa band appeared only in the Cdk5/p25 dou-
ble transfected cells. This band decreased in intensity when treated with 1 μM Roscovitine and did not show up in single 
transfected or untransfected cells. B. Western blot showing pSerCdk substrate, Cdk5 and p25 levels in cells transfected with 2, 
1.5 or 1 μg of each plasmid and in cells treated only with transfection reagent, Lipofectamine. The cells transfected with 1.5 μg 
of Cdk5 and p25 plasmid, i.e.3 μg total plasmid DNA, showed sufficient phosphorylation of Cdk substrates and least effect on 
cell morphology and viability (data not shown). C. Western blot showing a pSerCdk antibody immunoprecipitated sample from 
Cdk5/p25 transfected HEK293 cells probed with pSerCdk substrate antibody and with antibody to NMHC-B. Detection of the 
same band by both antibodies verifies that the 200 kDa band is NMHC-B.Journal of Biomedical Science 2009, 16:55 http://www.jbiomedsci.com/content/16/1/55
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Cdk5 inhibitors dose-dependently inhibit peptide substrate phosphorylation in a SPA assay Figure 2
Cdk5 inhibitors dose-dependently inhibit peptide substrate phosphorylation in a SPA assay. A. Roscovitine dose-
dependently inhibits substrate phosphorylation with IC50 280 nM. B. WL compound dose-dependently inhibits substrate phos-
phorylation with IC50 45 nM. C. AZ compound dose-dependently inhibits substrate phosphorylation with IC50 355 nM. Struc-
tures of these compounds are shown next to their respective inhibition curves.
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Cdk5 inhibitors dose-dependently inhibit NMHC-B phosphorylation in Cdk5/p25 transfected HEK293 cells Figure 3
Cdk5 inhibitors dose-dependently inhibit NMHC-B phosphorylation in Cdk5/p25 transfected HEK293 cells. A. 
Roscovitine dose-dependently inhibits pSerCdk phosphorylation with IC50 1.18 μM. B. WL compound dose-dependently inhib-
its pSerCdk phosphorylation with IC502.55 μM. C. AZ compound dose-dependently inhibits pSerCdk phosphorylation with 
IC50 4.36 μM. A Western blot of pSerCdk substrate in control and in cells treated with different concentrations of inhibitor is 
shown next to their respective inhibition curves.
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Warner-Lambert reference compound, and a compound
with an additional distinct structural class identified in
AstraZeneca. We also included a Cdk5 inactive compound
in order to demonstrate specificity of the measured signal.
All the three compounds demonstrated clear concentra-
tion dependent response, the IC50 values, as expected,
being higher than in the SPA based biochemical assay. The
magnitude of drop-offs between the assays for the differ-
ent chemical classes varied, which is a relatively common
phenomenon and can most likely be explained at least
partly by differences in their physical and chemical prop-
erties, as well as in cell permeability. The concentration
response curve for the AZ compound is not well defined
in the higher concentration area, which can also be seen
in the biochemical assay. This is likely to be due to the
poor solubility of the compound leading to precipitation
at higher concentrations.
The AZ compound used in this study is a novel type of
kinase inhibitor (Malmström and Viklund 2006). A close
analogue to it was co-crystallised with the Cdk5/p25 com-
plex and the X-ray structure showed that the ligand is not
Cdk5 phosphorylates NMHC-B in SH-SY5Y cells Figure 4
Cdk5 phosphorylates NMHC-B in SH-SY5Y cells. A. A Western blot showing a 200 kDa pSerCdk substrate band in 
undifferentiated and RA-differentiated SH-SY5Y cells. Phosphorylation of pSerCdk substrate is completely inhibited when cells 
are treated with 10 μM Roscovitine for 4 hours. B. A Western blot showing a pSerCdk antibody immunoprecipitated sample 
from SH-SY5Y cells probed with pSerCdk substrate antibody and with antibody to NMHC-B. Detection of the same band by 
both antibodies verifies that a 200 kDa band found in SH-SY5Y cells is NMHC-B. C. A Western blot showing pSerCdk sub-
strate and p25 levels in control and in p25 transfected SH-SY5Y cells. Transfection with p25 does not increase pSerCdk sub-
strate phosphorylation in SH-SY5Y cells. D. Densitometric quantification of pSerCdk phosphorylation in SH-SY5Y cells 
transfected with 8 μg p25 plasmid presented as % of control (mean ± SEM).
RA-diff.   Undiff.
pSerCdk 
substrate
C
o
n
t r
o
l
1
0
 
P M
 R
o
s
c
.
C
o
n
t r
o
l
1
0
 
P M
 R
o
s
c
.
A. B.
pSerCdk 
substrate
Myosin
191  kDa
191  kDa
C.
pSerCdk 
substrate
p25
C
o
n
t
r
o
l
p
2
5
 
8
 
P
g
D.
0
50
100
150
p25 8  μg
p
S
e
r
C
d
k
 
s
u
b
s
t
r
a
t
e
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
/
%
 
o
f
 
c
o
n
t
r
o
lJournal of Biomedical Science 2009, 16:55 http://www.jbiomedsci.com/content/16/1/55
Page 10 of 11
(page number not for citation purposes)
directly bound to the backbone (Glu 81 and Cys83) in the
ATP site of the kinase as is the usual case. Instead, a water
molecule was found to form a bridging interaction
between the ligand and the hinge backbone (Malmström
et al., unpublished results). The AZ compound is assumed
to bind in a similar fashion, although X-ray crystallogra-
phy would be required to confirm this.
Phosphorylation of NMHC-B was evident only in Cdk5/
p25 double transfected cells indicating that only Cdk5
phosphorylates this substrate in HEK293 cells. Cdk5
inhibitors concentration-dependently inhibited NMHC-B
phosphorylation and at higher concentrations phosphor-
ylation was totally blocked. Described assay with NMHC-
B phosphorylation as a read-out is thus very specific and
sensitive. However, a limitation of the system at present is
its relatively low throughput caused by the Western blot
based quantification of the phosphorylation signal. An
attempt to solve this could for instance be use of Image
analysis in a high content screening setting such as
ImageXpress.
Conclusion
A novel Cdk5 substrate, NMHC-B, was identified in this
study. Using phosphorylation of this substrate as a read-
out, we developed a specific and sensitive cellular assay
that can be used for validation of compounds designed to
inhibit Cdk5. A novel Cdk5 inhibitor was also pharmaco-
logically characterized in this assay system.
Abbreviations
AD: Alzheimer's disease; Cdk5: cyclin-dependent kinase;
HEK293: human embryonic kidney 293; NMHC-B: non-
muscle myosin heavy chain, type B; RA: retinoic acid; SPA:
Scintillation proximity assay.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AJ carried out experiments in SH-SY5Y cells, participated
in design of the study and drafted the manuscript. KA,
ACH and AJ all participated in experiments with HEK293
cells. KA also participated in the design of the study and
edited the manuscript. JO carried out the sequence analy-
sis using mass spectrometry and protein identification
using Mascot server. GH carried out SPA assays. JM was
responsible for the design and synthesis of the novel Cdk5
kinase inhibitor used in the study. GL designed the plas-
mids used in transfection experiments and participated in
the initial transfection experiments in HEK293 cells. MV
organized the study, participated in study design and
coordination and revised the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This study was partly supported by research grants from Stiftelsen Demen-
tia. We want to thank Rolf Olsson for help with figures and Richard Cow-
burn for critical reading of the manuscript.
References
1. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow
E, Tsai LH: A family of human CDC2-related protein kinases.
EMBO J 1992, 11:2909-2917.
2. Tsai LH, Delalle I, Caviness VS Jr, Chae T, Harlow E: p35 is a neural-
specific regulatory subunit of cyclin-dependent kinase 5.
Nature 1994, 371:419-423.
3. Tang D, Yeung J, Lee KY, Matsushita M, Matsui H, Tomizawa K,
Hatase O, Wang JH: An isoform of the neuronal cyclin-depend-
ent kinase 5 (cdk5) activator.  J Biol Chem 1995,
270:26897-26903.
4. Sharma P, Sharma M, Amin ND, Albers RW, Pant HC: Regulation
of cyclin-dependent kinase 5 catalytic activity by phosphor-
ylation.  Proc Natl Acad Sci 1999, 96:11156-11160.
5. Zheng M, Leung CL, Liem RK: Region-specific expression of cyc-
lin-dependent kinase 5 (cdk5) and its activators, p35 and p39,
in the developing and adult rat central nervous system.  J Neu-
robiol 1998, 35:141-159.
6. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH:
Conversion of p35 to p25 deregulates Cdk5 activity and pro-
motes neurodegeneration.  Nature 1999, 402:615-622.
7. Tseng HC, Zhou Y, Shen Y, Tsai LH: A survey of Cdk5 activator
p35 and p25 levels in Alzheimer's disease brains.  FEBS Lett
2002, 523:58-62.
8. Lee KY, Clark AW, Rosales JL, Chapman K, Fung T, Johnston RN:
Elevated neuronal Cdc2-like kinase activity in the Alzheimer
disease brain.  Neurosci Res 1999, 34:21-29.
9. Smith PD, Crocker SJ, Jackson-Levis V, Jordan-Sciutto KL, Hayley S,
Mount MP, O'Hare MJ, Callaghan S, Slack RS, Przedborski S, Anisman
H, Park DS: Cyclin-dependent kinase 5 is a mediator of
dopaminergic neuron loss in a mouse model of Parkinson's
disease.  Proc Natl Acad Sci 2003, 100:13650-13655.
10. Nguyen MD, Lariviére RC, Julien J-P: Deregulation of Cdk5 in a
mouse model of ALS: toxicity alleviated by perikaryal neuro-
filament inclusions.  Neuron 2001, 30:135-147.
11. Wang J, Liu SH, Fu YP, Wang JH, Lu YM: Cdk5 activation induces
hippocampal CA1 cell death by directly phosphorylating
NMDA receptors.  Nat Neurosci 2003, 6:1039-1047.
12. Sananbenesi F, Fischer A, Wang X, Schrick C, Neve R, Radulovic J,
Tsai LH: A hippocampal Cdk5 pathway regulates extinction of
contextual fear.  Nat Neurosci 2007, 10:1012-1019.
13. Fischer A, Sananbenesi F, Schrick C, Spiess J, Radulovic J: Cyclin-
dependent kinase 5 is required for associative learning.  J Neu-
rosci 2002, 22:3700-3707.
14. Ohshima T, Ogura H, Tomizawa K, Hayashi K, Suzuki H, Saito T,
Kamei H, Nishi A, Bibb JA, Hisanaga S, Matsui H, Mikoshiba K:
Impairment of hippocampal long-term depression and
defective spatial learning and memory in p35 mice.  J Neuro-
chem 2005, 94:917-925.
15. Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH: Opposing roles of
transient and prolonged expression of p25 in synaptic plastic-
ity and hippocampus-dependent memory.  Neuron 2005,
48:825-838.
16. Jämsä A, Hasslund K, Cowburn RF, Bäckström A, Vasänge M: The
retinoic acid and brain-derived neurotrophic factor differen-
tiated SH-SY5Y cell line as a model for Alzheimer's disease-
like tau phosphorylation.  Biochem Biophys Res Commun 2004,
319:993-1000.
17. Jämsä A, Bäckström A, Gustafsson E, Dehvari N, Hiller G, Cowburn
RF, Vasänge M: Glutamate treatment and p25 transfection
increase Cdk5 mediated tau phosphorylation in SH-SY5Y
cells.  Biochem Biophys Res Commun 2006, 345:324-331.
18. Barvian M, Boschelli DH, Cossrow J, Dobrusin E, Fattaey A, Fritsch A,
Fry D, Harvey P, Keller P, Garrett M, La F, Leopold W, McNamara D,
Quin M, Trumpp-Kallmeyer S, Toogood P, Wu Z, Zhang E:
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent
kinases.  J Med Chem 2000, 43:4606-4616.
19. Booth RJ, Chatterjee A, Malone TC: WO 01/55148.  .
20. Malmström J, Viklund J: WO 2006/004507.  .Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Biomedical Science 2009, 16:55 http://www.jbiomedsci.com/content/16/1/55
Page 11 of 11
(page number not for citation purposes)
21. Grant P, Sharma P, Pant HC: Cyclin-dependent protein kinase 5
(Cdk5) and the regulation of neurofilament metabolism.  Eur
J Biochem 2001, 268:1534-1546.
22. Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Man-
delkow E: Abnormal Alzheimer-like phosphorylation of Tau-
protein by cyclin-dependent kinases cdk2 and Cdk5.  FEBS Lett
1993, 336:417-424.
23. Paglini G, Pigino G, Kunda P, Morfini G, Maccioni R, Quiroga S, Fur-
reira A, Caceres A: Evidence for the participation of the neu-
ron-specific Cdk5 activator p35 during laminin-enhanced
axonal growth.  J Neurosci 1998, 18:9858-9869.
24. Cheung ZH, Fu AKY, Ip NY: Synaptic roles of Cdk5: Implica-
tions in higher cognitive functions and neurodegenerative
diseases.  Neuron 2006, 50:13-18.
25. Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna , Pant HC,
Brady RO, Martin LJ, Kulkarni AB: Targeted disruption of the
cyclin-dependent kinase 5 gene results in abnormal cortico-
genesis, neuronal pathology and perinatal death.  Proc Natl
Acad Sci 1996, 93:11173-11178.
26. Kwon YT, Tsai L-H, Crandall JE: Callosal axon guidance defects
in p35(-/-) mice.  J Comp Neurol 1999, 415:218-229.
27. Songyang Z, Lu KP, Kwon YT, Tsai LH, Filhol O, Cochet C, Brickey
DA, Soderling TR, Bartleson C, Graves DJ, DeMaggio AJ, Hoekstra
MF, Blenis J, Hunter T, Cantley LC: A structural basis for sub-
strate specificities of protein Ser/Thr kinases: primary
sequence preference of casein kinases I and II, NIMA, phos-
phorylase kinase, calmodulin-dependent kinase II, CDK5,
and ERK1.  Mol Cell Biol 1996, 16:6486-6493.
28. Sellers JR: Myosins: a diverse superfamily.  Biochim Biophys Acta
2000, 1496:3-22.
29. Bresnick AR: Molecular mechanisms of nonmuscle myosin-II
regulation.  Curr Opin Cell Biol 1999, 11:26-33.
30. Spudich A: Myosin reorganization in activated RBL cells cor-
relates temporally with stimulated secretion.  Cell Motil
Cytoskel 1994, 29:345-353.
31. Murakami M, Chauhan VPS, Elzinga M: Two nonmuscle myosin II
heavy chain isoforms expressed in rabbit brains: filament
forming properties, the effects of phosphorylation by Pro-
tein kinase C and Casein kinase II, and location of the phos-
phorylation sites.  Biochemistry 1998, 37:1989-2003.
32. Tanaka E, Fukunaga K, Yamamoto H, Iwasa T, Miyamoto E: Regula-
tion of the actin-activated Mg-ATPase of brain myosin via
phosphorylation by the brain Ca2+, calmodulin-dependent
protein kinases.  J Neurochem 1986, 47:254-262.
33. Ledee DR, Tripathi BK, Zelenka PS: The CDK5 activator, p39,
binds specifically to myosin essential light chain.  Biochem Bio-
phys Res Commun 2007, 354:1034-1039.